In this work, we focus on EpCAM-positive CTC from advanced NSCLC patients, and we approached their global gene expression profiling to better understand their biology and to identify and validate CTC-biomarkers with clinical utility in NSCLC. This evidence concerns the gene EPCAM and non-small cell lung carcinoma.